Dr. Aaron C. Logan, MD, PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 140
Licensed in California since 2007, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A101414 (first issued 2007; current) -
Hematology (Internal Medicine) Physician
CA license A101414 (first issued 2007; current) -
Internal Medicine Physician
CA license A101414 (first issued 2007; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
- Providence Santa Rosa Memorial Hospital Santa Rosa, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 140
- Services billed
- 748
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 262 | 81 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 65 | 55 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 50 | 17 |
| Collection of stem cells for transplantation | 15 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in San Francisco, CA | 149 |
| Gabapentin Other prescribers in San Francisco, CA | 52 |
| Posaconazole | 48 |
| Prednisone Other prescribers in San Francisco, CA | 34 |
| Atovaquone | 32 |
| Iclusig (ponatinib hcl) | 31 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in San Francisco, CA | 26 |
| Jakafi (ruxolitinib phosphate) | 25 |
| Levofloxacin Other prescribers in San Francisco, CA | 23 |
| Ursodiol Other prescribers in San Francisco, CA | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 48 payments worth $97,909 in total to this clinician.
| Amgen Inc. | $71,762 |
|---|---|
| Servier Bioinnovation | $7,590 |
| Autolus Inc | $5,639 |
| Adaptive Biotechnologies Corporation | $4,000 |
| Syndax Pharmaceuticals, Inc. | $2,932 |
| Sanofi-aventis U.S. LLC | $2,750 |
| Novartis Pharmaceuticals Corporation | $2,415 |
| Daiichi Sankyo Inc. | $650 |
| Compensation for services other than consulting (speaking, faculty) | $56,458 |
|---|---|
| Consulting Fee | $23,734 |
| Travel and Lodging | $16,595 |
| Food and Beverage | $1,122 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,977 |
| Amgen Inc. Jan 1, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $10,928 |
| Amgen Inc. Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $10,928 |
| Amgen Inc. Aug 30, 2025 | Travel and Lodging travel to Bogota, Colombia · in-kind | $7,898 |
| Amgen Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $7,684 |
| Servier Bioinnovation Oct 20, 2025 | Consulting Fee Asparlas · Oncology | $7,590 |
| Amgen Inc. Feb 6, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $7,184 |
| Amgen Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $5,640 |
| Autolus Inc May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,551 |
| Amgen Inc. Aug 27, 2025 | Consulting Fee BLINCYTO · Oncology | $4,098 |
All 31 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,800 |
| Syndax Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY · in-kind | $132 |
| Amgen Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $7,684 |
| Servier Bioinnovation Oct 20, 2025 | Consulting Fee Asparlas · Oncology | $7,590 |
| Amgen Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $5,640 |
| Amgen Inc. Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $10,928 |
| Amgen Inc. Aug 30, 2025 | Travel and Lodging travel to Bogota, Colombia · in-kind | $7,898 |
| Amgen Inc. Aug 30, 2025 | Travel and Lodging travel to Bogota, Colombia · in-kind | $266 |
| Amgen Inc. Aug 30, 2025 | Travel and Lodging travel to Bogota, Colombia · in-kind | $72.76 |
| Sanofi-aventis U.S. LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| Amgen Inc. Aug 27, 2025 | Consulting Fee BLINCYTO · Oncology | $4,098 |
| Novartis Pharmaceuticals Corporation Jul 11, 2025 | Consulting Fee | $2,415 |
| Amgen Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $12,977 |
| Sanofi-aventis U.S. LLC Jun 14, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Amgen Inc. Jun 10, 2025 | Consulting Fee BLINCYTO · Oncology | $2,049 |
| Autolus Inc May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,551 |
| Amgen Inc. May 29, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to CHICAGO, IL · in-kind | $459 |
| Adaptive Biotechnologies Corporation May 1, 2025 | Consulting Fee clonoSEQ · Devices | $2,400 |
| Adaptive Biotechnologies Corporation May 1, 2025 | Consulting Fee clonoSEQ · Devices | $1,600 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Sanofi-aventis U.S. LLC Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Sanofi-aventis U.S. LLC Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Sanofi-aventis U.S. LLC Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) REZUROCK · Oncology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Amgen Inc. Feb 10, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $104 |
| Amgen Inc. Feb 8, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $150 |
| Amgen Inc. Feb 7, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $150 |
| Amgen Inc. Feb 7, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $20.95 |
| Amgen Inc. Feb 6, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $7,184 |
| Amgen Inc. Feb 6, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $150 |
| Amgen Inc. Feb 6, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Nice, France · in-kind | $141 |
| Amgen Inc. Jan 1, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $10,928 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $385,085 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic…
Amgen Inc. - A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Sanofi US Services Inc. · Active, not recruiting · NCT06143891 - A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant…
National Marrow Donor Program - AUTO1-AL1
Autolus Inc - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program - Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.